Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

Tipranks - Tipranks - Sat Apr 11, 3:53AM CDT

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca today and set a price target of p17,600.00.

Easter Sale - 70% Off TipRanks

According to TipRanks, Weston is a 4-star analyst with an average return of 10.2% and a 69.00% success rate. Weston covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Sanofi.

In addition to UBS, AstraZeneca also received a Buy from Citi’s Graham Parry in a report issued today. However, on March 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

See Insiders’ Hot Stocks on TipRanks >>

Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).